Reynolds CP - Search Results

1

Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference.

Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA; ALLNA 2008 Conference. Horton TM, et al. Among authors: reynolds cp. Pediatr Blood Cancer. 2010 Jul 1;54(7):872-8. doi: 10.1002/pbc.22414. Pediatr Blood Cancer. 2010. PMID: 20127846 Free PMC article.

2

N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.

Wang H, Maurer BJ, Reynolds CP, Cabot MC. Wang H, et al. Among authors: reynolds cp. Cancer Res. 2001 Jul 1;61(13):5102-5. Cancer Res. 2001. PMID: 11431347

3

N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.

O'Donnell PH, Guo WX, Reynolds CP, Maurer BJ. O'Donnell PH, et al. Among authors: reynolds cp. Leukemia. 2002 May;16(5):902-10. doi: 10.1038/sj.leu.2402485. Leukemia. 2002. PMID: 11986953

4

Retinoid therapy of high-risk neuroblastoma.

Reynolds CP, Matthay KK, Villablanca JG, Maurer BJ. Reynolds CP, et al. Cancer Lett. 2003 Jul 18;197(1-2):185-92. doi: 10.1016/s0304-3835(03)00108-3. Cancer Lett. 2003. PMID: 12880980 Review.

5

Ceramide synthesis and metabolism as a target for cancer therapy.

Reynolds CP, Maurer BJ, Kolesnick RN. Reynolds CP, et al. Cancer Lett. 2004 Apr 8;206(2):169-80. doi: 10.1016/j.canlet.2003.08.034. Cancer Lett. 2004. PMID: 15013522 Review.

6

Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.

Batra S, Reynolds CP, Maurer BJ. Batra S, et al. Among authors: reynolds cp. Cancer Res. 2004 Aug 1;64(15):5415-24. doi: 10.1158/0008-5472.CAN-04-0377. Cancer Res. 2004. PMID: 15289350

7

Evaluating response to antineoplastic drug combinations in tissue culture models.

Reynolds CP, Maurer BJ. Reynolds CP, et al. Methods Mol Med. 2005;110:173-83. doi: 10.1385/1-59259-869-2:173. Methods Mol Med. 2005. PMID: 15901935 Review.

8

The pediatric preclinical testing program: description of models and early testing results.

Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, Liu T, Billups CA, Khan J, Ansher S, Zhang J, Smith MA. Houghton PJ, et al. Among authors: reynolds cp. Pediatr Blood Cancer. 2007 Dec;49(7):928-40. doi: 10.1002/pbc.21078. Pediatr Blood Cancer. 2007. PMID: 17066459

9

Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.

Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, Keshelava N, Maris JM, Keir ST, Wu J, Smith MA. Houghton PJ, et al. Among authors: reynolds cp. Pediatr Blood Cancer. 2008 Jan;50(1):37-45. doi: 10.1002/pbc.21214. Pediatr Blood Cancer. 2008. PMID: 17420992

10

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.

Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, Lock R, Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA. Maris JM, et al. Among authors: reynolds cp. Pediatr Blood Cancer. 2008 Mar;50(3):581-7. doi: 10.1002/pbc.21232. Pediatr Blood Cancer. 2008. PMID: 17457854

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters